A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers
- PMID: 10670566
- DOI: 10.1099/0022-1317-49-2-157
A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers
Abstract
A whole-cell pertussis vaccine, each dose consisting of 250 microg of protein, was given intranasally four times at weekly intervals to six adult volunteers. All vaccinees responded with increases in nasal fluid IgA antibodies to Bordetella pertussis whole-cell antigen. Three vaccinees with high nasal antibody responses also developed increased serum IgA and IgG antibodies to this antigen. Salivary antibody responses to the whole-cell antigen, as well as antibodies in serum and secretions to pertussis toxin (PT) and filamentous haemagglutinin (FHA) were negligible, except for a moderate increase in nasal fluid antibodies to FHA. Unexpectedly, the same vaccinees developed significant rises in nasal and salivary IgA antibodies to meningococcal outer-membrane antigens, whereas corresponding serum IgA and IgG antibodies were unchanged. Thus it appears that mucosal immunisation may induce secretory antibodies with broader specificities than can be found in serum.
Similar articles
-
Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.Vaccine. 2003 Mar 7;21(11-12):1165-73. doi: 10.1016/s0264-410x(02)00516-9. Vaccine. 2003. PMID: 12559794
-
Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.Vaccine. 2000 May 8;18(22):2323-30. doi: 10.1016/s0264-410x(00)00024-4. Vaccine. 2000. PMID: 10738087
-
Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.Vaccine. 1998 Dec;16(20):2039-46. doi: 10.1016/s0264-410x(98)00077-2. Vaccine. 1998. PMID: 9796062
-
Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.Clin Exp Immunol. 2006 Jun;144(3):543-51. doi: 10.1111/j.1365-2249.2006.03097.x. Clin Exp Immunol. 2006. PMID: 16734625 Free PMC article.
-
[Bacteria and bacterial vaccines as nonspecific modulators of immunological reactivity].Zh Mikrobiol Epidemiol Immunobiol. 1980 Nov;(11):5-11. Zh Mikrobiol Epidemiol Immunobiol. 1980. PMID: 7004007 Review. Russian. No abstract available.
Cited by
-
The Role of Mucosal Immunity in Pertussis.Front Immunol. 2019 Jan 14;9:3068. doi: 10.3389/fimmu.2018.03068. eCollection 2018. Front Immunol. 2019. PMID: 30692990 Free PMC article. Review.
-
BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.Infect Immun. 2024 Mar 12;92(3):e0022323. doi: 10.1128/iai.00223-23. Epub 2024 Feb 7. Infect Immun. 2024. PMID: 38323817 Free PMC article.
-
Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.Infect Immun. 2006 Feb;74(2):968-74. doi: 10.1128/IAI.74.2.968-974.2006. Infect Immun. 2006. PMID: 16428742 Free PMC article. Clinical Trial.
-
Generating enhanced mucosal immunity against Bordetella pertussis: current challenges and new directions.Front Immunol. 2023 Feb 21;14:1126107. doi: 10.3389/fimmu.2023.1126107. eCollection 2023. Front Immunol. 2023. PMID: 36895562 Free PMC article.
-
Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.Infect Immun. 2003 Feb;71(2):726-32. doi: 10.1128/IAI.71.2.726-732.2003. Infect Immun. 2003. PMID: 12540551 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous